Top-line data for two identical Phase III studies of faricimab, Roche Holding AG’s novel bispecific antibody product for retinal diseases, suggest it is no better than Bayer AG’s Eylea but still likely to prove a thorn in the side of Novartis AG’s newcomer Beovu.
The two trials – YOSEMITE and RHINE – in a total of 1,891 patients with diabetic macula edema (DME) both...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?